Assiut University: Purpura, Thrombocytopenic, Idiopathic trials
The registry lists 16 Purpura, Thrombocytopenic, Idiopathic studies with Assiut University as lead sponsor. 6 are open to participants now and 0 have results posted.
Phase 4 3No phase 13(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Selective Mediterranean Diet in Immune ThrombocytopeniaNot yet recruitingNCT07798050Not applicable
- Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on TreatmentNot yet recruitingNCT07059910
- Steroid Resistance in Pediatric Immune Thrombocytopenic PurpuraNot yet recruitingNCT06601543
- Explore the Relationship Between Platelet Count and Bleeding Score in ITPRecruitingNCT06273956
- Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic PurpuraNot yet recruitingNCT06137105
- Immune Markers in Pediatric ITP on Second Line TherapyNot yet recruitingNCT06093529
- COVID-19 Vaccine and Development of Immune Thrombocytopenic PurpuraStatus unknownNCT05455983
- Prognostic Value of CD Markers in Immune Thrombocytopenic PurpuraStatus unknownNCT04311593
- Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?Status unknownNCT04128358Not applicable
- Eltrombopag in Chronic ITPStatus unknownNCT04102033Phase 4
- Effect of DNMT SNPs on DNA Methylation in Primary ITPStatus unknownNCT04100876
- Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its LevelCompletedNCT03864796
- Lymphocyte Counts in Immune Thrombocytopenic PurpuraStatus unknownNCT03244410
- Reposition of Second Line Treatment in Chronic Immune ThrombocytopeniaCompletedNCT03229746Phase 4
- Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic PurpraStatus unknownNCT03183284
- Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic PurpuraStatus unknownNCT03172676Phase 4